Use-dependent block of voltage-gated Cav2.1 Ca2+ channels by petasins and eudesmol isomers.
Migraine is a frequent and often disabling disease. Treatment is unsatisfactory in many patients. A disturbed dynamic balance between excitatory and inhibitory signal processing with enhanced cortical activity probably underlies common forms of migraine. Presynaptic voltage-gated Ca(2+) channels are critical determinants of neurotransmitter release and also contribute to trigeminovascular signal transduction. Because clinical evidence exists for migraine-prophylactic actions of Petasites hybridus extracts, we investigated whether petasins comprising the main constituents of the extract inhibit currents through presynaptic Ca(v)2.1 channels expressed in Xenopus laevis oocytes. P. hybridus extract (0.02 mg/ml), petasin, neopetasin, isopetasin, S-petasin, and iso-S-petasin (50 microM) were weak tonic blockers of Ca(v)2.1-mediated barium currents (I(Ba)) during infrequent depolarizations (0.1 Hz), but their inhibitory potency increased at higher stimulation rates (1 Hz), indicating preferential block of open and/or inactivated channels. Sulfur-containing compounds (S-petasin, Iso-S-petasin) were the most potent significantly promoting the accumulation of Ca(v)2.1 channel in inactivated states during pulse trains (I(Ba) decrease during 1-Hz pulse trains: control, 45%, S-petasin, 79%; iso-S-petasin, 80%). For the Eucalyptus williamsiania sesquiterpenes alpha- and gamma-eudesmol, a comparable use-dependent inhibition was found in addition to a tonic block component. Alpha-eudesmol and petasins accelerated the voltage-dependent inactivation of Ca(v)2.1 channels during depolarizations. We demonstrate that S-petasin, iso-S-petasin, and eudesmol are Ca(v)2.1 channel inhibitors preferentially acting as use-dependent channel blockers and with the sulfur-containing substituent in position 3 of the petasins serving as important functional feature. The Ca(v)2.1-inhibitory properties of these petasins may contribute to migraine-prophylactic properties described for P. hybridus extracts.
Horak
Silja
S
Institute of Pharmacy, Peter-Mayr-Strasse 1/I, A-6020 Innsbruck, Austria.
Koschak
Alexandra
A
Stuppner
Hermann
H
Striessnig
Jörg
J
D000818:Animals; D002121:Calcium Channel Blockers / Q000302:isolation & purification / Q000494:pharmacology*; D020864:Calcium Channels, N-Type / Q000378:metabolism* / Q000502:physiology; D020865:Calcium Channels, P-Type / Q000378:metabolism; D020907:Calcium Channels, Q-Type / Q000378:metabolism; D005260:Female; D009822:Oils, Volatile / Q000302:isolation & purification / Q000494:pharmacology*; D036901:Petasites / Q000737:chemistry / Q000502:physiology*; D010936:Plant Extracts / Q000302:isolation & purification / Q000494:pharmacology; D012717:Sesquiterpenes / Q000302:isolation & purification / Q000494:pharmacology*; D014982:Xenopus laevis
D002121:Calcium Channel Blockers; D020864:Calcium Channels, N-Type; D020865:Calcium Channels, P-Type; D020907:Calcium Channels, Q-Type; D009822:Oils, Volatile; D010936:Plant Extracts; D012717:Sesquiterpenes; C418727:petasin